OBR Daily Commentary

forumImage

First-Line Lung Cancer Data and Other New Research from Merck’s Broad Oncology Program to be Presented at AACR Annual Meeting

(Merck) Mar 14, 2018 - Late-breaker presentation of overall survival and progression-free survival results from pivotal phase 3 KEYNOTE-189 trial with KEYTRUDA ® (pembrolizumab) plus pemetrexed and platinum chemotherapy in first-line treatment of advanced nonsquamous non-small cell lung cancer; first-time KEYTRUDA data including recurrence-free survival from phase 3 KEYNOTE-054 Study, in collaboration with EORTC, in patients with stage III surgically resected high-risk melanoma.

Read Article arrow

H. Jack West, MD (Posted: March 15, 2018)

quotes

This presentation of data from KEYNOTE-189, CheckMate-227, IMpower150, and some other trials of immunotherapy combinations in first line advanced NSCLC will be in the same blockbuster session on late Monday morning at AACR. This two hour period will likely have a significant impact on lung cancer practice this year. All eyes interested in the field should be watching around that time.

quotes

Reply

Add Comment 1 Comment(s)

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...